Jatin Shah Net Worth

The estimated Net Worth of Jatin Shah is at least $169 mil dollars as of 17 February 2022. Jatin Shah owns over 1,306 units of Karyopharm Therapeutics Inc stock worth over $95,793 and over the last 5 years he sold KPTI stock worth over $72,879. In addition, he makes $0 as Executive Vice President e Chief Medical Officer at Karyopharm Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jatin Shah KPTI stock SEC Form 4 insiders trading

Jatin has made over 9 trades of the Karyopharm Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,306 units of KPTI stock worth $15,829 on 17 February 2022.

The largest trade he's ever made was buying 23,250 units of Karyopharm Therapeutics Inc stock on 7 May 2021 worth over $199,950. On average, Jatin trades about 3,583 units every 56 days since 2019. As of 17 February 2022 he still owns at least 129,450 units of Karyopharm Therapeutics Inc stock.

You can see the complete history of Jatin Shah stock trades at the bottom of the page.

Jatin Shah biography

Dr. Jatin Shah M.D. serves as Executive Vice President, Chief Medical Officer of the Company. Dr. Shah joined Karyopharm in May 2017 as Vice President, Clinical Strategy, and was appointed Senior Vice President, Clinical Development in April 2018 and Executive Vice President, Chief Medical Officer in July 2019. Prior to joining Karyopharm, Dr. Shah held numerous roles at The University of Texas MD Anderson Cancer Center. From September 2007 to August 2016, Dr. Shah served as an Assistant Professor, Associate Professor, and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine. Dr. Shah received his M.D. from The Ohio State University College of Medicine, Columbus, Ohio and holds a degree in Mechanical Engineering from The Ohio State University. Dr. Shah completed his residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine.

How old is Jatin Shah?

Jatin Shah is 45, he's been the Executive Vice President e Chief Medical Officer of Karyopharm Therapeutics Inc since 2019. There are 20 older and 2 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.

What's Jatin Shah's mailing address?

Jatin's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON, MA, 02459.

Insiders trading at Karyopharm Therapeutics Inc

Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic..., eMikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.

What does Karyopharm Therapeutics Inc do?

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Complete history of Jatin Shah stock trades at Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc executives and stock owners

Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ran Frenkel,
  Chief Development Operations Officer
• Michael Kauffman,
  Co-Founder, Chief Executive Officer and Director
• Sharon Shacham,
  President, Chief Scientific Officer
• Christopher Primiano,
  Executive Vice President, Chief Business Officer, General Counsel and Secretary
• Dr. Michael G. Kauffman M.D., Ph.D.,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Michael G. Kauffman,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Sharon Shacham M.B.A., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Sharon Shacham,
  Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board
• Michael P. Mason CPA, M.B.A.,
  Sr. VP, CFO & Treasurer
• Mansoor Mirza,
  Director and Clinical Advisor
• Barry Greene,
  Lead Independent Director
• Deepa Pakianathan,
  Independent Director
• Garen Bohlin,
  Independent Director
• Dr. Mansoor Raza Mirza M.D.,
  Clinical Consultant, Member of Scientific Advisory Board & Independent Director
• Mikael Dolsten,
  Independent Director
• Dr. Mansoor Raza Mirza,
  Clinical Consultant, Member of Scientific Advisory Board & Director
• Richard A. Paulson M.B.A.,
  Pres, CEO & Director
• Richard Paulson,
  Independent Director
• Christy Oliger,
  Director
• Perry Monaco,
  Senior Vice President of Sales
• Jatin Shah,
  Executive Vice President, Chief Medical Officer
• Tanya Lewis,
  Executive Vice President, Chief Regulatory Officer and Quality Officer
• Michael Mason,
  Chief Financial Officer, Senior Vice President, Treasurer
• James Accumanno J.D.,
  Chief Compliance Officer
• Elhan Webb C.F.A.,
  Sr. VP of Investor Relations
• Lisa Meletta J.D.,
  VP of Legal & Chief Compliance Officer
• Michael J. Mano J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Pierre S. Sayad M.S., Ph.D.,
  VP of Global Medical & Scientific Affairs
• Cameron Peters,
  VP of Fin., Assistant Treasurer & Principal Accounting Officer
• Ran Frenkel R.Ph., RPh,
  Exec. VP & Chief Devel. Officer
• Zhen Su,
  
• Carsten Thiel,
  Director
• Kenneth E Weg,
  Director
• J. Scott Garland,
  Director
• Justin A Renz,
  EVP, CFO & Treasurer
• Michael Falvey,
  EVP, CFO & Treasurer
• Peter Honig,
  Director
• Anand Varadan,
  EVP, Chief Commercial Officer
• Cameron Peters,
  VP of Finance
• Marcin Hadjimichael Andreas...,
  
• Paul Brannelly,
  SVP, FIN & ADMIN, SEC & TRES
• Ltd Czernik Marcin Hadjimic...,
  
• Ltd Czernik Marcin Hadjimic...,
  
• John Demaree,
  Chief Commercial Officer
• Deepika Pakianathan,
  
• Chen Schor,
  
• Stephen Mitchener,
  SVP, Chief Business Officer
• Michael Mano,
  SVP, General Counsel&Secretary
• Sohanya Roshan Cheng,
  EVP & Chief Commercial Officer
• Stuart Poulton,
  EVP, Chief Development Officer
• Reshma Rangwala,
  EVP & Chief Medical Officer